Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
clay crap not only curse
this management needs to go.
Shorts %
Date Symbol Name Short Volume Long Volume Total Volume Short%
2016-08-24 AMDA Amedica Corporation 5770182 4780199 10550381 55
this means they are safe for next year and do not need to get more convertibles to market this new product.
I was talking about this technology in 2014 when rthchild were helping this company to reorganize. I invested in that company for this technology but big fish took it private. Now this technology is in market. SUNE can use these ready to use cheap solar panels and bring cost down and get a lot of orders like the one they got in Chilea.
SunEdison Semiconductor agrees to be bought for $683 million
shorts need to cover by Tuesday to avoid next run up or get crushed.
if sun stops working then we have bigger problems for our survival in our solar system then sune stock price.
Another Fumbled SunEdison Deal -- Market Talk
Thursday 08/18/2016 11:32 AM ET - Dow Jones News
11:32 ET - Vivint Solar was left at the M&A altar by faltering solar power developer SunEdison earlier this year. It's claiming $1B in damages, an amount that means significant clout in SunEdison's bankruptcy--if Vivint can prove it. Last week, Vivint and SunEdison were nearing a second deal, this time an agreement on how and when to fight the original busted deal claim out in court. This week, it's no deal again when it comes to the litigation schedule, Vivint's lawyer said, asking a judge to push aside the bankruptcy shield that's protecting SunEdison from hostile suits. (peg.brickley@wsj.com)
this one need to hit 200DMA high before it hit the breaks.
TERP was 40/Share about a year ago. are they going to get that price for their Class A shares?
from the Form 8K
As of January 21, 2016, there are 74,490,039 shares of Common Stock issued and outstanding and 1,029,291 shares of Common Stock to be delivered pursuant to the mandatory exercise of the unexercised Series C Warrants. Upon surrender of all 92,069 Series C Warrants and the delivery of the 1,029,291 shares of Common Stock, the Company will have 75,519,330 shares of Common Stock issued and outstanding.
=======================================
In addition, approximately 120.2 million shares are reserved for the convertible note, related Series D Warrants and other derivative securities resulting in approximately 4.3 million shares available for issuance.
====================================================
As of January 21, 2016, there are 88,347 shares of Series E Convertible Preferred Stock outstanding (each 60 shares of Series E Convertible Preferred Stock are convertible into four shares of common stock). There are no Series C Warrants or Unit Purchase Options outstanding.
=================================================
Exhibit A
Capitalization Table January 21, 2016 (in million of shares)
Authorized Shares 200
Common Stock Issued and Outstanding* 75.5
Pre-funded Rights to Acquire Common Stock 0
TOTAL Shares Outstanding (including pre-paid rights) 75.5
Shares Reserved for Convertible Note Holders and Related Derivatives 120
Shares Reserved for Other Derivatives, including Series E Preferred Stock 0.2
Unreserved and Unissued Shares 4.3
Series C Warrants
Series E Convertible Preferred Stock** 0 0.1
==============================================================
* Includes approximately 1 million shares of common stock to be delivered upon the surrender the 92,069 converted Series C Warrants that remain to be surrendered as of this date
**Each share of Series E Convertible Preferred Stock is convertible into 4/60th of one share of common stock—were all Series E Convertible Preferred Stock to be converted into common shares, the Company would issue 5,890 shares of its common stock to the holders of the Series E Convertible Preferred Stock.
=================================================================
check this one. this was released in Jan.
Great Basin Announces Conversion of Remaining Series C Warrants
I think that they still have series D and Series E convertible notes which needs to do their conversions so I am expecting more dilution even after R/S. after last R/S this stock was at $8 and now in pennies. if they do one more then they almost cleaned all investment of all the long investors still dreaming to recover their money. I would ask to read more about series D and E convertible notes. Do your DD.
why is this down. Is this another convertible stock dilution or something else?
most of the big lab companies can perform simple blood, urine and stool tests and send results to hospitals and clinics via EMR systems not on papers. The small clinics do not want to perform blood, urine and stool tests in local clinics anyway and in case of emergency they send patients to Emergency Department of nearby hospital. Emergency clinics or hospitals have some lab company presence inside the hospital or nearby for quick results. where is your market?
IMO this estimate is more realistic then other ones are talking about.
how about series E and another one that you were just talking about earlier..
I think that before 3/31/16 you will get hit by another convertible notes financing. are you ready for this?
there are so many companies making these test machines. for some of them you do not need to go to hospital and they have simple home kits. what are the chances that these products will get any decent market share. looking at losses and income this business seems to be growing on the convertible stocks money not on sales or revenue.
the stock float is a lot bigger now. do you know about recent mega dilution before making your charts? add those stocks in the chart and check where it will go after adding new convertible stocks in the list. May be you are making this graph at original stock float (around 11 Millions). add another about 100 million to this float and then make this graph again.
compare their income and loss/per share. their sale is nothing compare to loss. someone is filling pockets with salaries and bonuses but no value for share holders. wait for next dilution and few will make salary and bonuses for them after FDA approval and you share holders will keep holding your bags because before you get your breakeven next dilution will wipe out your recovery. IMO do your DD
after next dilution what will be the value of this triple stocks. I know one of my friend and he bought at 8 after r/s and u can see his stocks value now. may be think what will be after another dilution.
so they are already in the process of another dilution. cool you proved me right here.
the way leadership is handling finance this one fits in otc not in Nasdaq. this leadership do not care about investors and ready to ruin investor's money any time thru toxic financing.
http://semiengineering.com/thinking-outside-the-chip/
Home > Low Power-High Performance > Thinking Outside The Chip
Low Power-High Performance
Thinking Outside The Chip
Intel joins AMD, IBM on advanced packaging; performance is the key driver.
January 14th, 2016 - By: Ed Sperling
popularity
Intel will begin adding 2.5D and 3D packaging into its processors, following the lead set by IBM and AMD in recognizing that new packaging approaches are essential for improving performance and lowering power.
This shift won’t derail the semiconductor industry’s efforts to the reach future process nodes or continually shrink features, but it does add context for other factors that increasingly will help define technology progress in the future. Those factors include:
• Shortening distances that signals must travel between the processor, memories and I/Os;
• Reducing the resistance to driving those signals by using faster interconnects with improved bandwidth—thereby reducing both power and heat;
• The ability to optimize performance, power and cost more easily through different packaging options, and
• Improved time to market by using customized configurations from parts developed at a variety of process geometries.
For Intel, this is more than just a statement of direction. It’s a modification of a 2D approach to chip design that has defined the company since its inception. And if the past is any indication, it will be used as a stamp of approval by other chipmakers as they migrate to smaller geometries.
“We will start this year,” said Babek Sabi, Intel corporate vice president and director of assembly and test technology development. “That will be for servers. Adding this for the mass market involves us and memory suppliers and some others. There are a lot of people talking about it now. We expect it will move down in the market in the latter part of this decade.”
While Intel may be able to manage all of the pieces itself—manufacturing, packaging, chip development—it’s not so clear how the rest of the industry will fare with an advanced packaging model.
Some interesting facts about 22 NM tri gate transistors. you can compare it with the size of CPU with few millions 7nm or 5nm transistors.
http://download.intel.com/newsroom/kits/22nm/pdfs/22nm_Fun_Facts.pdf
check the security filings section and read about reverse splits.
On December 8, 2015, we held a special meeting (the “Special Meeting”) of our stockholders. At the Special Meeting, the stockholders approved an amendment to the Company’s Seventh Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock at a ratio between 1 to 50 and 1 to 60, such ratio to be determined by the board of directors of the Company (the “Board”), and to reduce the par value of the Company’s common stock from $0.001 to $0.0001 (the “Reverse Stock Split”). Immediately after the Special Meeting, the Board held a meeting and approved the Reverse Stock Split at a ratio of 1 to 60, such Reverse Stock Split went effective at 12:01 am EST on December 11, 2015. Unless we indicate otherwise, the information in this prospectus reflects the impact of the Reverse Stock Split.
thanks for sharing this stocker. I am hoping that EPGL and ATT research will work out. I hope that these EPGL will be able to work on ATT network to help government and non-government organizations.
Check the Intel's Processor sizes and expected date when these will be available in market. I think that 10/5nm is so small that it can easily fit in a contact lens. What do you think?
http://www.alphr.com/news/374626/intel-reveals-roadmap-to-5nm-process
People on this board were saying same thing about the COO contract in 2014. Even at that time many people inside COO were not aware of this contract because research and development information's are kept confidential from non-related departments and normally research is performed in other countries research labs. For a company like intel, they would not tell anyone until they have not filed the patent. I wrote same thing earlier for COO and writing again same. We will find out when right time will come.
Please check email sent by the COO IR and Viking posted in other message about EPGL and COO settlement. Just ask yourself that why market pioneer companies like intel and ATT are working with this OTC company. There must be some technology that made sense to them. Sometime you need to challenge your thoughts to learn new things.
Read about the EPGL lens and how it can perform these tasks if you have a way to read data collected by the sensors installed in these lens.
Google patents a wearable that tells you to take your medications when you eat
Jordan Novet January 9, 2016 6:19 PM
Tags: Alphabet, Google, Verily
Read my old message sent on Friday:
mds3579 Member Level Friday, 01/08/16 02:50:43 PM
Re: vikingzskillz post# 94813
Post # of 95158
Google was in talks with EPGL first but stepped back. I think that google is a software company and they can not develop products for eye so they decided to work with Novartis so Novartis can build lens and they just make software for that lens to perform what they want it to do. I think that Novartis is in talks with EPGL to get the basics working and if required to deal with patents agreements stuff just like COO.
good job Vik!
I think that next quarter report will show cash amount that they have available. If we see a big change in cash amount then we would be able to estimate amount based of available cash.
VR products should be in market before 2020. Google and other companies are planning for this Virtual reality world by 2020. But we will see different products in markets making their space and preparing market for these products. you can see a lot big of oculus rift type products. this is just start of this world like we had big stone size cell phone in early 90's and you can compare the old and new cell phones. compare their functions and sizes then this will be all clear for you.
Google was in talks with EPGL first but stepped back. I think that google is a software company and they can not develop products for eye so they decided to work with Novartis so Novartis can build lens and they just make software for that lens to perform what they want it to do. I think that Novartis is in talks with EPGL to get the basics working and if required to deal with patents agreements stuff just like COO.